Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus

Journal of the American Academy of Dermatology

Volumn 50, Issue 6, 2004, Pages 946-948

  Ziemer, Mirjana ^a   Gruhn, Bernd ^a   Thiele, Jens J ^a   Elsner, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; PIMECROLIMUS; PREDNISOLONE;

ACUTE MYELOMONOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC GRAFT REJECTION; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; LIVER FUNCTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 2542453799     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.02.010     Document Type: Article

References (17)

1. Breathnach SM, Katz SI. Immunopathology of cutaneous graft versus host disease. Am J Dermatopathol 1987;9:343-8.
2. Hood AF, Soter NA, Rappeport J, Gigli I. Graft-versus-host reaction: cutaneous manifestations following bone marrow transplantation. Arch Dermatol 1977;113:1087-91.
3. Mauduit G, Claudy A. Cutaneous expression of graft-vs-host disease in man. Semin Dermatol 1988;7:149-55.
4. Horn TD. Effector cells in cutaneous graft-versus-host disease. Who? What? When? Where? How? Br J Dermatol 1999;141:779-80.
5. Yoo YH, Park BS, Whitaker-Menezes D, Korngold R, Murphy GF. Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. J Cutan Pathol 1998;25:426-34.
6. Snover DC. Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol 1984;15:202-5.
7. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
8. Rowell NR, Goodfield MJD. Graft-versus-host reactions. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook/Wilkinson/Ebling textbook of dermatology. Oxford: Blackwell Science, 1998. p. 2518.
9. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeger R, Orfanos CE. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994;14:845-8.
10. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlober P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000;42:134-5.
11. Grundmann-Kollmann M, Martin H, Ludwig R, Klein S, Boehncke WH, Hoelzer D, et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002;74:1631-3.
12. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001;137:1202-6.
13. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-41.
14. Billich A, Aschauer H, Stuetz A. Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. 63rd Annual Meeting, Soc Invest Dermatol, May 15-18, 2002, Los Angeles [abstract]. J Invest Dermatol 2002;119:346.
15. Billich A, Aschauer H, Stuetz A. Pimecrolimus is less skin permeable than tacrolimus or corticosteroids. 11th congress of the European Academy of Dermatology and Venerology, October 3-5, 2002, Prague [abstract]. J Eur Acad Dermatol Venereol 2002;16:257.
16. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-40.
17. Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002;8:206-12.